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Introduction
Psoriasis is a systemic inflammatory disorder with 
a prevalence ranging from 0.5% to as high as 
11.4% in some countries.1 It is characterized clin-
ically by the presence of erythematous, scaly, and 
well-demarcated cutaneous plaques that classi-
cally occur on the extensor surfaces. On a micro-
scopic and molecular level, the disorder is thought 
to be caused by dysregulated interaction between 
the immune system and keratinocytes. Although 
mild psoriasis is generally well-managed with 
localized treatments, some patients with more 
severe disease presentation may require systemic 
therapy with immunomodulatory drugs.
The newest therapies for psoriasis are monoclonal 
antibodies that target the inflammatory cytokines 
involved in the pathogenesis of psoriasis. 
These drugs, known as biologics, have generated 
significantly improved outcomes for patients with 
moderate-to-severe psoriasis. Tildrakizumab, a 
specific inhibitor of interleukin (IL)-23, has 
recently gained approval by the United States 
Food and Drug Administration (US FDA) as well 
as the European Medicines Agency (EMA) for 
patients with moderate-to-severe plaque psoriasis. 
This discussion provides an overview of existing 
literature on the mechanism, efficacy, and safety 
of tildrakizumab. It also aims to analyze the utility 
of tildrakizumab in comparison with other biolog-
ics and define areas in which additional investiga-
tion is warranted to better understand its risks and 
benefits.
Mechanism of action
The earliest biologics for psoriasis introduced to 
the market were inhibitors of the acute phase 
Tildrakizumab in the treatment of psoriasis: 
latest evidence and place in therapy
Deeti J. Pithadia, Kelly A. Reynolds, Erica B. Lee, Wilson Liao and Jashin J. Wu
Abstract: Psoriasis is a chronic inflammatory disorder that is clinically characterized by 
scaly cutaneous plaques. New evidence suggests that dysregulation of interleukin (IL)-23, 
a key cytokine in the T-helper-17 pathway, plays a vital role in the development of psoriatic 
systemic inflammation. The novel biologic medication tildrakizumab is among the first 
drugs with specific action against IL-23 that has recently been approved by the United States 
Food and Drug Administration and the European Medicines Agency for moderate-to-severe 
psoriasis. Tildrakizumab has been shown in large randomized controlled trials to be effective 
in improving skin manifestations as well as enhancing quality of life outcomes in patients with 
psoriasis. Its simple dosing, prolonged duration of action, and mild adverse event profile make 
it a practical option for patients; however, only a small number of trials have investigated the 
clinical effectiveness of tildrakizumab, and long-term data regarding the drug’s efficacy and 
safety are currently limited. Hence, further research is needed to better understand the risks 
and benefits of tildrakizumab. This review summarizes and analyzes phase I, phase II, and 
phase III clinical trials that investigate the mechanism, pharmacokinetics, efficacy, and safety 
of tildrakizumab. It also identifies areas in which additional studies are warranted to further 
elucidate the advantages of tildrakizumab over other biologic therapies.
Keywords: biologics, IL-23 inhibitor, psoriasis, tildrakizumab
Received: 16 October 2018; revised manuscript accepted: 1 July 2019.
Correspondence to: 
Jashin J. Wu 
Dermatology Research 
and Education Foundation, 
Irvine, CA 92620, USA
jashinwu@gmail.com
Deeti J. Pithadia 
Medical College of 
Georgia, Augusta 
University, Augusta, GA, 
USA
Kelly A. Reynolds 
University of Cincinnati, 
College of Medicine, 
Cincinnati, OH, USA
Erica B. Lee 
University of Hawaii, 
Department of Medicine, 
Santa Barbara Cottage 
Hospital, Santa Barbara, 
CA, USA
Wilson Liao 
Department of 
Dermatology, Psoriasis 
and Skin Treatment 
Center, University of 
California-San Francisco, 
San Francisco, CA, USA
865658 TAJ0010.1177/2040622319865658Therapeutic Advances in Chronic DiseaseDJ Pithadia, KA Reynolds
review-article20192019
Review
Therapeutic Advances in Chronic Disease 10
2 journals.sagepub.com/home/taj
cytokine tumor necrosis factor-alpha (TNF-α). 
Newer-generation biologics inhibit the cytokine 
components of the IL-12/T-helper-1 (Th1) path-
way, which promotes a powerful inflammatory 
response through interferon gamma and IL-2,2 or 
the IL-23/Th17 pathway, which is best known for 
generating an immune response against bacterial 
and fungal antigens.3 Structurally, IL-12 and 
IL-23 are heterodimers that share a p40 subunit. 
IL-12 additionally contains a p35 subunit and 
IL-23 contains a p19 subunit. It was initially 
believed that the efficacy of biologics inhibiting 
p40, such as ustekinumab, was due to inhibition 
of IL-12, which was considered the integral 
cytokine for the majority of inflammation in pso-
riasis since it initiates a strongly proinflammatory 
Th1 response. More recently, however, it has 
been found that dysregulated IL-23 production 
likely plays a more significant role than IL-12 
overproduction in driving psoriatic cutaneous 
inflammation. In mouse models, direct intrader-
mal administration of IL-23 into the skin caused 
psoriasis-like inflammation and epidermal thick-
ening, an effect not observed following injection 
of IL-12.4 Furthermore, IL-23p19 and 
IL-12/23p40 mRNA levels have been found to be 
elevated in psoriatic skin lesions while IL-12p35 
levels are normal.5,6 Genome-wide association 
studies have also demonstrated that single nucle-
otide polymorphisms in IL-23p19 and the IL-23 
receptor are associated with psoriasis.7 
Tildrakizumab, a humanized antibody, selectively 
inhibits IL-23p19, and it is among the first 
approved psoriasis therapies that is specific for 
IL-23. Other novel therapies that specifically tar-
get IL-23p19 include guselkumab, which gained 
EMA approval for psoriasis in November 2017,8 
and risankizumab, which is actively undergoing 
phase III trials for efficacy and safety.3
Pharmacokinetics and drug interactions
An open-label, phase I trial conducted by 
Zandvliet and colleagues (Table 1) was one of the 
earliest studies of the bioavailability of tildraki-
zumab. A total of 53 healthy patients without pso-
riasis were randomized to receive subcutaneous 
(SC) tildrakizumab at 50 mg, 200 mg, or 400 mg 
doses. Drug exposure over time was found to 
increase consistently with increased dosing. The 
maximum concentration of drug, total drug expo-
sure over time, mean drug half-life, and median 
time to maximum drug concentration were com-
parable across Chinese, Japanese, and White 
patients, which suggests that race may not signifi-
cantly affect the metabolism of tildrakizumab. 
Both SC and intravenous (IV) dosing at 10 mg/kg 
were found to be well-tolerated by participants.9
There have been two randomized, placebo-con-
trolled, phase I trials that tested the pharmacoki-
netic properties of IV tildrakizumab in healthy 
patients at doses ranging from 0.1 to 10 mg/kg and 
SC tildrakizumab at doses ranging from 50 to 
200 mg (Table 1). These studies concluded that 
the maximum concentration and total drug expo-
sure over time increased proportionally with both 
SC and IV dosing, corroborating the findings of 
Zandvliet and colleagues. It was also found that 
50 mg SC dosing had a bioavailability of 80% 
(versus 0.5 mg/kg IV dosing) and 200 mg SC dos-
ing had a bioavailability of 73% (versus 3 mg/kg IV 
dosing). Both of these bioavailabilities were 
deemed to result in adequate drug exposure for 
obtaining clinical efficacy.10,12
Another trial has observed that tildrakizumab 
serum levels are generally higher in patients who 
demonstrated a 75% improvement in Psoriasis 
Area and Severity Index (PASI) scores (PASI-75) 
compared with those who did not show clinical 
improvement. However, in the group receiving 
the highest dose (200 mg SC), drug levels were 
similar in participants both with and without a 
favorable clinical response (Table 1).11 The half-
life of tildrakizumab is estimated to be between 3 
and 4 weeks, such that it may be dosed infre-
quently as many weeks apart.9,12
Currently, limited understanding exists regarding 
the interactions of tildrakizumab with other drugs. 
It is known that the reduction of systemic inflam-
mation with biologic use may iatrogenically alter 
drug metabolism by cytochrome P450 (CYP) 
enzymes, as observed in patients with rheumatoid 
arthritis.13 Conversely, it has been hypothesized 
that biologics can normalize aberrant CYP activity 
in patients with psoriasis by blocking inflamma-
tory cytokines that may alter the enzymes’ action.14 
A recent open-label, dual-period, fixed-sequence 
study found no significant changes in the pharma-
cokinetics or appearance of serum metabolites of 
CYP-metabolized drugs with the administration 
of tildrakizumab. Though this study was limited 
by a small sample size and a lack of blinding, it 
provides evidence that the incidence of drug–drug 
interactions in patients with psoriasis treated with 
tildrakizumab may be minimal.15
DJ Pithadia, KA Reynolds et al.
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Laboratory studies of efficacy
Kopp and colleagues performed microscopic, 
immunohistochemical, and gene expression test-
ing of the lesional skin of patients at baseline and 
following 63 or 84 days of initiating treatment with 
various doses of tildrakizumab.12 Cutaneous 
expression of IL-23p19, the target of tildraki-
zumab, was successfully reduced following tildrak-
izumab treatment. On microscopic examination, 
treated skin showed a resolution of epidermal 
thickening but had not fully reverted to the nonle-
sional state. A histopathological psoriasis severity 
score was found to be significantly reduced in skin 
of patients treated with tildrakizumab, with an 
average reduction of 67%. This effect was particu-
larly prominent in patients treated with 3 mg/kg 
and 10 mg/kg tildrakizumab, who showed espe-
cially significant reductions in epidermal, vascu-
lar, and inflammatory parameters. Furthermore, 
expression of the proliferation markers Ki67 and 
epithelial antigen keratin 16 in the skin were nor-
malized following tildrakizumab treatment, corre-
lating with mitosis reduction in the suprabasal 
epidermal layer. Finally, tildrakizumab dosing also 
decreased the levels of inflammatory cells that are 
generally elevated in psoriasis, including that of 
epidermal and dermal CD4+ and CD8+ T-cells, 
dermal myeloid dendritic cells, CD11c+ myeloid 
dendritic cells, and CD15+ neutrophils.12
Clinical efficacy and dosing
Kopp and colleagues conducted one of the first 
randomized, double-blinded, placebo-controlled 
trials that investigated the clinical efficacy of tild-
rakizumab.12 A total of 77 patients aged 18–
65 years old with moderate-to-severe plaque 
psoriasis were administered IV injections of three 
doses of 0.05, 0.1, 0.5, 3, or 10 mg/kg tildraki-
zumab, with treatment intervals ranging from 4 
to 8 weeks. Nearly all patients treated with 
3 mg/kg and 10 mg/kg regimens reached PASI-75 
between 16 and 28 weeks following initiation of 
treatment, and a significant portion of two groups 
also achieved PASI-90 by 28 weeks. Mean 
improvement in PASI scores were up to 80% for 
all groups by 28 weeks. A clinically meaningful 
response, defined as a PASI score reduction of 
50% from baseline, persisted through 36 weeks 
of monitoring after administration of the final 
dose in both of these treatment groups.12 These 
results were limited by a small sample size pre-
venting appropriate dose–response correlation. 
Nonetheless, they provided preliminary evidence 
that specifically targeting IL-23p19 with tildraki-
zumab results in the symptomatic improvement 
of psoriasis.
A multicenter, placebo-controlled, phase IIb trial 
affirmed the above results and provided a dose–
response correlation for treatment. It included 64 
clinic study sites in North America, Japan, and 
Europe, and it followed a total of 355 adult 
patients for 52 weeks. Patients were administered 
5 mg, 25 mg, 100 mg, or 200 mg tildrakizumab SC 
at week 0, week 4, and then every 12 weeks until 
week 52. The percentages of patients that reported 
that their skin manifestations were ‘cleared’ or 
‘minimal’, corresponding to a Physician’s Global 
Assessment (PGA) score of 0 or 1, were 33%, 
58%, 62% and 74% for the 5 mg, 25 mg, 100 mg, 
and 200 mg groups, respectively. At the primary 
endpoint at week 16, PASI-75 responses were 
found to be 33%, 64%, 66%, and 74% for the 
5 mg, 25 mg, 100 mg, and 200 mg groups, respec-
tively. From 16 to 52 weeks, the dose of tildraki-
zumab was increased in nonresponders and 
decreased to 25 mg or kept constant in those with 
a favorable clinical response. Over 90% of those 
who received a constant dose attained PASI-75, 
compared with just 70% of those whose doses 
were reduced. In the group receiving a higher 
dose, the percentage of patients who attained 
PASI-75 increased with time. After 1 year of treat-
ment, more than 90% of patients receiving doses 
of 100 mg or 200 mg of tildrakizumab from initia-
tion of the study maintained PASI-75 6 months 
after treatment cessation, compared with just 68% 
of those who underwent dose reduction at week 
16. This suggests that maintaining 100 mg to 
200 mg dosing may provide a lasting clinical ben-
efit even after discontinuation.11
The phase III, parallel group, double-blinded, 
randomized, controlled reSURFACE1 and reSUR-
FACE2 trials randomly assigned 1549 patients 
with moderate-to-severe psoriasis in North 
America, Europe, Australia, Israel, and Japan into 
groups based on the region of origin, body weight, 
and previous exposure to biologic therapy (Table 1). 
Each group was treated with placebo, 100 mg 
tildrakizumab or 200 mg tildrakizumab at week 0, 
week 4, and then every 12 weeks subsequently, and 
data were reported through 28 weeks from initia-
tion of the studies. In reSURFACE1, at week 12, 
64% and 62% of patients in the 100 mg and 200 mg 
groups, respectively, attained PASI-75, compared 
with only 6% in the placebo group. Similar trends 
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were observed in Dermatology Quality of Life 
Index (DLQI) and PGA scores of these patient 
groups as well as in analogous reSURFACE2 
experiments. At 28 weeks, 90% and 84% of patients 
who initially responded to treatment with 200 mg 
tildrakizumab maintained PASI-75 in reSUR-
FACE1 and reSURFACE2, respectively. In 
reSURFACE1, a group of patients received ther-
apy with placebo for 12 weeks and were then rand-
omized to receive tildrakizumab 100 mg or 200 mg; 
by week 28, their clinical responses were compara-
ble with those treated with the analogous doses of 
tildrakizumab from the initiation of the study.16
The results of a 3-year follow up of a pooled analysis 
of individuals enrolled in reSURFACE1 and 
reSURFACE2 who had at least 75% improvement 
from baseline in PASI-75 at week 20 were recently 
publicized. It was found that PASI-75 or greater 
was maintained in 91% of individuals who contin-
ued the 100-mg dosing and in 92% of those con-
tinuing the 200-mg dosing. A subset of PASI-75 
responders within reSURFACE1 were switched to 
placebo at week 28. A total of 54% and 47% of indi-
viduals relapsed in the groups formerly on the 100-
mg and 200-mg dosing, respectively. The median 
time to relapse was very long, at 226 days in the 
100 mg group and 258 days in the 200 mg group.17
The current US FDA-approved and EMA-
approved dosing of tildrakizumab consists of 
100 mg injected SC at weeks 0 and 4, followed by 
100 mg SC every 12 weeks thereafter,18,19 a regi-
men that aims to optimize cost-effectiveness while 
maintaining appropriate skin relief and quality of 
life improvement. The EMA label additionally 
states that patients with a high disease burden 
and body weight may benefit from 200 mg dos-
ing,19 although this has not been formally vali-
dated by any randomized controlled trials. Future 
prospective studies may focus on delineating the 
ideal time of treatment and frequency of dosing 
for the quickest response and longest mainte-
nance following discontinuation of treatment. 
Furthermore, studies that evaluate the efficacy of 
tildrakizumab in different variants of psoriasis 
and patients with psoriatic arthritis and other sys-
temic symptoms are merited.
Immunogenicity
With the use of biologics, patients occasionally 
develop antidrug antibodies (ADAs) against the 
biologic that prevent or diminish drug efficacy.20,21 
Many of the aforementioned trials evaluated the 
development and effects of ADAs against tildraki-
zumab. Of those who were pretreatment negative 
for ADAs, between 8% and 18% of patients devel-
oped ADAs.9,11,12 Overall, two studies found 
decreased tildrakizumab levels in a small fraction 
of the patients with positive ADA measure-
ments,9,12 and one noted a significantly decreased 
tildrakizumab half-life in one-third of patients 
with positive ADAs.10 Most studies did not spe-
cifically comment on the relationship between 
clinical response and immunogenicity, although 
Kopp and colleagues reported that none of the 
ADA-positive patients had a diminished PASI 
response compared with those who did not have 
decreased drug levels.12 While Zandvliet and col-
leagues outlined the lower limit of quantification 
of both the ADA and drug level measurement 
assays10 and Papp and colleagues described the 
use of an electrochemiluminescence-based immu-
noassay to screen patients for ADA presence,11 
the remainder of the studies failed to comment on 
a specific method of measuring ADA levels. Other 
limitations of many of these trials include a small 
cohort size and a lack of differentiation between 
primary and secondary nonresponse. Additionally, 
each of the studies varied in the time frames of 
ADA measurement following the initiation of 
treatment, making head-to-head comparisons 
among studies challenging. Future research may 
focus on determining the efficacy of antibody sup-
pressants used for the management of ADAs 
against other biologics, such as methotrexate, in 
preventing a lack of response and treating loss of 
response to tildrakizumab.
Safety and adverse events
The majority of the aforementioned randomized 
trials found that approximately half of patients 
treated with tildrakizumab experienced at least 
one adverse event.9,11,12,16 The most consistently 
reported of these across the trials were headache 
(24–27%) and nasopharyngitis (8–39%).10,11,12,16 
Injection site-associated complications, including 
hematomas, pain, and erythema were also com-
monly reported (1–15%).9,10,16 Dysmenorrhea 
was experienced by 2 of 29 patients in one of the 
studies.10 One trial observed that 9 of 307 patients 
treated with tildrakizumab versus none of the 45 
patients receiving placebo experienced hyperten-
sion. However, six out of these nine patients were 
found to be hypertensive or pre-hypertensive at 
baseline.11 A patient in another trial experienced 
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convulsions, but it was discovered that the patient 
had a history of sleep deprivation, alcohol con-
sumption, and a recent reduction in benzodiaze-
pine use.12
In spite of the aforementioned findings, tildra-
kizumab has been found to be, overall, well- 
tolerated. Most adverse events were mild and did 
not require treatment cessation and there was no 
dose-related increase in adverse events observed. 
Tildrakizumab did not cause any significant 
changes in vital signs and electrocardiogram 
results,10,11,12 and the risk of cardiovascular events 
was not significantly increased compared with that 
of untreated patients with moderate-to-severe 
psoriasis.11 In the reSURFACE trials, inflamma-
tory bowel disease, which has been reported to 
worsen with therapeutic inhibition of IL-17,22 was 
not observed in patients treated with tildraki-
zumab over 28 weeks of treatment.16 Furthermore, 
a recent pooled analysis of reSURFACE1 and 
reSURFACE2 reported that the 3-year safety pro-
file of tildrakizumab is comparable with placebo, 
particularly with regards to the rates of serious 
infection and major cardiovascular events.17
There is a theoretical increased risk of infection 
and malignancy with the use of any immunosup-
pressant medications, including biologics.11,16 
Isolated cases of bacterial arthritis, epiglottitis, 
malignant melanoma and other unspecified 
malignancies have been reported in patients 
treated with tildrakizumab.11 Interestingly, how-
ever, compared with the inhibition of other 
inflammatory cytokines, inhibition of IL-23 may 
only minimally impair the ability to generate 
immune response. It has been observed in animal 
models that targeting IL-23p19 is associated with 
a lower risk of Salmonella, Candida, and 
Mycobacterium infections compared with the tar-
geting of IL-12/23p40.11 Furthermore, Candida 
infections, which are slightly more common in 
patients on IL-17 inhibitors, were considered 
‘infrequent’ in one trial, though the particular fre-
quency was not noted.11
A major limitation of our knowledge regarding 
the side-effect profile of tildrakizumab is that 
much of the evidence available has been pooled 
from different studies with various endpoints.23 
More data regarding long-term safety outcomes 
of individuals formerly enrolled in various tild-
rakizumab trials would be of utility to further our 
understanding of the real-world scope and 
severity of adverse effects related to therapy. In 
particular, follow-up studies investigating the 
incidence of infection and cancer in patients 
treated with tildrakizumab compared with those 
treated with other biologics may be warranted.
Comparisons to other biologics
The reSURFACE2 trial also directly compared 
the efficacy of tildrakizumab with that of etaner-
cept. In this study, 310 patients were dosed with 
tildrakizumab 100 mg and 314 with tildrakizumab 
200 mg. A total of 313 patients were treated with 
etanercept 50 mg twice weekly, which is the maxi-
mum approved dose for psoriasis. Compared 
with patients treated with etanercept, a signifi-
cantly greater proportion of patients in the tild-
rakizumab 200 mg group achieved PASI-75 and 
PGA responses of 0 or 1 by week 12 as well as 
DLQI responses of 0 or 1 by week 28; however, 
tildrakizumab 100 mg did not have significantly 
more clinical efficacy than etanercept at week 12. 
Etanercept and tildrakizumab had similar rates 
and profiles of adverse events, though injection 
site erythema was more common in etanercept. 
This study also noted that suicidal ideation, 
observed in patients treated with the IL-17RA 
inhibitor brodalumab,24 was not reported in the 
cohort treated with tildrakizumab.11
The remainder of studies that compare the effi-
cacy of tildrakizumab with that of other biologics 
synthesize data from independently performed 
randomized controlled trials. A study that 
reviewed phase II data available for tildrakizumab 
and guselkumab, which share the IL-23p19 tar-
get, found that the percentage of patients reach-
ing PGA of 0 or 1 and PASI-75 was greater than 
70% following 16 weeks of treatment with each 
agent at doses closest to those utilized in phase III 
clinical trials (200 mg tildrakizumab at weeks 0, 4, 
and then every 12 weeks; 100 mg guselkumab 
every 8 weeks).25 Another study pooled PASI 
reduction scores and percentage of patients 
achieving a PGA of 0 or 1 from reSURFACE1 
and reSURFACE2 as well as the phase III 
VOYAGE 1 and VOYAGE 2 trials analyzing the 
efficacy of guselkumab. Comparison of results 
found that tildrakizumab may be less clinically 
effective than guselkumab; however, this is not 
entirely reliable since the reSURFACE trials ini-
tially evaluated patients at 12 weeks and the 
VOYAGE trials at 16 weeks.26 A recent meta-
analysis synthesized data from 24 randomized 
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placebo-controlled trials to compare the efficacy 
and safety of IL-12/23 inhibitor ustekinumab, 
IL-17 inhibitors secukinumab, ixekizumab and 
brodalumab, and the selective IL-23 inhibitors 
guselkumab and tildrakizumab. The results of the 
study suggested that compared with placebo, 
100 mg tildrakizumab incurs a lower risk of 
adverse events related to achieving PASI-75, 
PASI-90, and PGA 0/1 compared with standard 
doses27 of nearly every other biologic; the only 
exception was a slightly lower risk of adverse 
events related to achieving PGA 0/1 when using 
ustekinumab 45 mg.28 These results indicate that 
tildrakizumab may be safer than other approved 
biologics. At present, further meta-analyses, par-
ticularly studies that include data from trials of 
TNF-α inhibitors, would be useful to better elu-
cidate the efficacy and tolerability of tildraki-
zumab compared with other biologics.
Conclusion
Tildrakizumab, an inhibitor of IL-23p19, has been 
demonstrated to significantly improve both cuta-
neous manifestations and quality of life in patients 
with moderate-to-severe psoriasis. Given the addi-
tional advantages of the simplicity of dosing, long 
period of action and mild adverse effects, it is a 
feasible therapeutic option for patients with mod-
erate-to-severe psoriasis. However, since these 
claims are based on the findings of a limited num-
ber of clinical trials with shortcomings such as 
small cohort sizes and early endpoints, further 
study of the long-term efficacy and safety of tild-
rakizumab in direct comparison with other biolog-
ics on the market is still warranted. Investigations 
of the utility of tildrakizumab in patients who expe-
rience less common forms of psoriasis, systemic 
comorbidities, and failure of response to multiple 
biologic agents, as well as further meta-analyses 
comparing tildrakizumab with other biologics may 
help to better elucidate the complete spectrum of 
therapeutic potential for this novel drug and to 
better define its place in therapy.
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